Side-by-side look at BeiGene and Zai’s cancer pipelines: Data Byte

Apart from PD-1 and PARP inhibitors, the cancer pipelines of two of China’s leading public biotechs BeiGene and Zai hold few overlapping targets, though the two are exploring a similar range of technologies including bispecific antibodies, synthetic lethality approaches and kinase inhibitors.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and  Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) each market a PARP1/2 inhibitor for ovarian cancer in China and are aiming to expand the drugs into new indications. BeiGene’s pamiparib is approved in patients with 3L germline BRCA mutations, in whom PARP inhibition creates a synthetic lethal interaction with the mutations that kills the tumor cells. Zai’s niraparib is approved for first- and second-line maintenance treatment and was studied in women with or without BRCA mutations. Next up for both PARP inhibitors is gastric cancer and other solid tumors...